Comparison of changes in respiratory function and exercise oxygen uptake with losartan versus enalapril in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy

American Journal of Cardiology

Volumn 80, Issue 12, 1997, Pages 1572-1576

  Guazzi, Marco ^a   Melzi, Gloria ^a   Agostoni, Piergiuseppe ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; LOSARTAN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONGESTIVE HEART FAILURE; ENZYME INHIBITION; EXERCISE TOLERANCE; FEMALE; HEART DILATATION; HEART MUSCLE ISCHEMIA; HEART PRELOAD; HUMAN; LUNG FUNCTION TEST; MALE; OXYGEN CONSUMPTION; PRIORITY JOURNAL; RESPIRATORY FUNCTION; VASCULAR RESISTANCE; VITAL CAPACITY;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; ASPIRIN; CARDIOMYOPATHY, DILATED; CROSS-OVER STUDIES; CYCLOOXYGENASE INHIBITORS; DOUBLE-BLIND METHOD; ENALAPRIL; EXERCISE TEST; HEART FAILURE, CONGESTIVE; HEMODYNAMIC PROCESSES; HUMANS; LOSARTAN; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; OXYGEN CONSUMPTION; PULMONARY DIFFUSING CAPACITY; PULMONARY VENTILATION; RESPIRATORY MECHANICS;

EID: 0031434653     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(97)00781-9     Document Type: Article

References (27)

1. Kraemer MD, Kubo SH, Rector ST, Brunsvold N, Bank AJ. Pulmonary and peripheral vascular factors are important determinants of peak exercise oxygen uptake in patients with heart failure. J Am Coll Cardiol. 21:1993;641-648.
2. Siegel JL, Miller A, Brown LK, De Luca A, Tierstein AJ. Pulmonary diffusing capacity in left ventricular failure. Chest. 98:1990;550-553.
3. Naum C, Sciurba FC, Rogers RM. Pulmonary function abnormalities in chronic severe cardiomyopathy preceding cardiac transplantation. Am Rev Resp Dis. 145:1992;1334-1338.
4. Puri S, Baker BL, Dutka DP, Oakley CM, Hughes JMB, Cleland JGF. Reduced alveolar-capillary membrane diffusing capacity in chronic heart failure. Its pathophysiological relevance and relationship to exercise performance. Circulation. 91:1995;2769-2774.
5. Chua TP, Coats AJS. The lungs in chronic heart failure. Eur Heart J. 16:1995;882-887.
6. Guazzi M, Marenzi GC, Alimento M, Contini M, Agostoni PG. Improvement of alveolar-capillary diffusing capacity with enalapril in chronic heart failure and counteracting effect of aspirin. Circulation. 95:1997;1930-1936.
7. Eberhardt RT, Kevak RM, Kang PM, Frishman WH. Angiotensin II receptor blockade an innovative approach to cardiovascular pharmacotherapy . J Clin Pharmacol. 33:1993;1023-1038.
8. Linz W, Wiemer G, Gohlke P, Unger T, Schölkens BA. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev. 47:1995;25-49.
9. Awan NA, Mason DT. Direct selective blockade of the vascular angiotensin II receptors in therapy for hypertension and severe congestive heart failure. Am Heart J. 131:1996;177-185.
10. Gottlieb SS, Dickstein K, Fleck E, Kostis J, Levine TB, Le Jemtel T, De Kock M. Hemodynamic and neurohumoral effects of the angiotensin II antagonist losartan in patients with congestive heart failure. Circulation. 88:1993;1602-1609.
11. Crozier I, Ikram H, Awan N, Cleland J, Stephen N, Dickstein K, Frey M, Young J, Klinger G, Makris L, Rucinska E. Losartan in heart failure. Hemodynamic effects and tolerability. Circulation. 91:1995;691-697.
12. Goodfriend TL, Elliott ME, Catt KJ. Angiotensin receptors and their antagonists. N Engl J Med. 334:1996;1649-1654.
13. Towned JN, Doran J, Lote CJ, Davies MK. Peripheral hemodynamic effects of inhibition of prostaglandin synthesis in congestive heart failure and interactions with captopril. Br Heart J. 73:1995;434-441.
14. Pitt B, Chang P, Timmermans PBMWVM. Angiotensin II receptor antagonists and design of the evaluation of Losartan in the elderly (ELITE) trial. Cardiovasc Drug Ther. 9:1995;693-700.
15. Cotes JE, Dabbs JM, Elwood PC, Hall AM, McDonald A, Saunders MJ. Iron deficiency anemia its effect on transfer factor for the lung (diffusing capacity) and ventilation and cardiac frequency during submaximal exercise . Clin Sci. 42:1972;325-335.
16. Knudson RJ, Levowitz MD, Holberg CJ, Burrow B. Changes in the normal maximal expiratory flow-volume curve with growth and aging. Am Rev Resp Dis. 127:1983;725-734.
17. Guazzi M, Marenzi GC, Assanelli E, Perego GB, Cattadori G, Doria E, Agostoni PG. Evaluation of the dead space/tidal volume ratio in patients with chronic congestive heart failure. J Cardiac Failure. 1:1995;401-408.
18. Evans MA, Burnett JC Jr, Redfield MM. Effect of low dose aspirin on cardiorenal function and acute hemodynamic response to enalapril in a canine model of severe heart failure. J Am Coll Cardiol. 25:1995;1445-1450.
19. Narang R, Swedberg K, Cleland JGF. What is the ideal study design for evaluation of treatment for heart failure? Insights from trials assessing the effect of ACE inhibitors on exercise capacity. Eur Heart J. 17:1996;120-134.
20. Mancini DM, Eisen H, Kussmaul W, Mull R, Edmunds LH, Wilson JR. Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. Circulation. 83:1991;778-786.
21. 2 determination in chronic heart failure is it still of value? Eur Heart J. 15:1994;495-502.
22. West JB, Mathieu Costello O. Stress failure of pulmonary capillaries role in lung and heart disease . Lancet. 340:1992;762-767.
23. Ontkean M, Gay R, Greenberg B. Diminished endothelium-derived relaxing factor activity in an experimental model of chronic heart failure. Circ Res. 69:1991;1088-1096.
24. Huang H, Arnal JF, Ilorens-Cortes C, Challah M, Alhenc-Gelas F, Corvol P, Michel JB. Discrepancy between plasma and lung angiotensin-converting enzyme activity in experimental congestive heart failure. Circ Res. 75:1994;454-461.
25. Myers J, Froelicher VF. Hemodynamic determinants of exercise capacity in chronic heart failure. Ann Int Med. 115:1991;377-386.
26. Cleland JGF, Bulpitt CJ, Falk RH, Findlay IN, Oakley CM, Murray G, Poole-Wilson PA, Prentice CRM, Sutton GC. Is aspirin safe for patients with heart failure? Br Heart J. 74:1995;215-219.
27. Blaufarb IS, Sonnenblick EH. The renin-angiotensin system in left ventricular remodeling. Am J Cardiol. 77:1996;8C-16C.